ADVIK LABORATORIES LTD.

Advik Laboratories Ltd has reported its investor complaint status for the quarter ended September 30, 2026. As per SEBI regulations, the company has provided a statement detailing the number of complaints. For the quarter, there were zero complaints pending at the beginning, zero received during the quarter, zero disposed of, and zero remaining unresolved at the end of the period. This indicates effective grievance redressal mechanisms for the quarter.

Advik Laboratories Ltd. (now MPS Pharmaa Limited) held its 32nd Annual General Meeting (AGM) on September 29, 2026. All resolutions presented to the shareholders were approved with the required majority. Key approvals included the adoption of audited financial statements for the fiscal year ending March 31, 2026, the re-appointment of Mr. Ram Niwas Sharma as a Non-Executive Director, the re-appointment of M/s. Nemani Garg Agarwal & Co. as Statutory Auditors for a five-year term, the appointment of Ms. Anchal Goyal as an Independent Director for a five-year term, and approval for related party transactions and transactions under Section 185 of the Companies Act, 2013.

Advik Laboratories Ltd (now MPS Pharmaa Limited) held its 32nd Annual General Meeting (AGM) on September 29, 2026. All resolutions presented to the shareholders were approved with the required majority. Key approvals included the adoption of audited financial statements for the fiscal year ending March 31, 2026, the re-appointment of Mr. Ram Niwas Sharma as a Non-Executive Director, the re-appointment of M/s. Nemani Garg Agarwal & Co. as Statutory Auditors for a five-year term, the appointment of Ms. Anchal Goyal as an Independent Director for a five-year term, and approval for related party transactions and transactions under Section 185 of the Companies Act, 2013.

MPS Pharmaa Limited (formerly Advik Laboratories Limited) announced that all resolutions proposed at its 32nd Annual General Meeting (AGM) held on September 29, 2026, were duly passed by shareholders. Key approvals included the adoption of the Audited Financial Statements for the financial year ended March 31, 2026. Shareholders also re-appointed Mr. Ram Niwas Sharma as a Non-Executive Director and M/s. Nemani Garg Agarwal & Co. as Statutory Auditors for a further term of five years. Additionally, the appointment of Ms. Anchal Goyal as an Independent Director for five years was approved, along with Related Party Transactions and transactions under Section 185 of the Companies Act, 2013.

Advik Laboratories Ltd. (now MPS Pharmaa Limited) held its 32nd Annual General Meeting (AGM) on September 29, 2026. All resolutions presented to the shareholders were approved with the required majority. Key approvals included the adoption of audited financial statements for the fiscal year ending March 31, 2026, the re-appointment of Mr. Ram Niwas Sharma as a Non-Executive Director, the re-appointment of M/s. Nemani Garg Agarwal & Co. as Statutory Auditors for a five-year term, the appointment of Ms. Anchal Goyal as an Independent Director for a five-year term, and approvals for related party transactions and transactions under Section 185 of the Companies Act, 2013.

MPS Pharmaa Limited (formerly Advik Laboratories Ltd) announced that all resolutions proposed at its 32nd Annual General Meeting (AGM) held on September 29, 2026, were duly passed by shareholders with the requisite majority. Key approvals included the adoption of the Audited Financial Statements for the year ended March 31, 2026, and the re-appointment of Mr. Ram Niwas Sharma as a Non-Executive Director. Shareholders also approved the re-appointment of M/s. Nemani Garg Agarwal & Co. as Statutory Auditors for a five-year term and the appointment of Ms. Anchal Goyal as an Independent Director for five years. Additionally, approval was granted for Related Party Transactions and transactions under Section 185 of the Companies Act, 2013.

Advik Laboratories Ltd held its 32nd Annual General Meeting (AGM) on September 29, 2026, where shareholders approved all resolutions. Key approvals include the adoption of audited financial statements for FY26, re-appointment of Mr. Ram Niwas Sharma as a Non-Executive Director, and re-appointment of M/s. Nemani Garg Agarwal & Co. as Statutory Auditors for a five-year term. Additionally, related party transactions and transactions under Section 185 of the Companies Act, 2013 were approved. Ms. Anchal Goyal was appointed as an Independent Director for a five-year term.

Advik Laboratories Ltd has announced the closure of its trading window for directors, promoters, KMPs, designated employees, and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will remain shut from October 1st, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ending September 30th, 2026. The date for the board meeting to approve these results will be communicated separately.

Advik Laboratories Ltd has announced the closure of its trading window for directors, promoters, KMPs, designated employees, and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will remain shut from October 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ending September 30, 2026. The date for the Board of Directors' meeting to approve these results will be communicated separately.

Advik Laboratories Ltd (now MPS Pharmaa Limited) has announced a book closure period from September 23, 2026, to September 29, 2026. This closure is in accordance with Regulation 42 of the SEBI (LODR) Regulations, 2015, and is for the purpose of the company's upcoming Annual General Meeting (AGM). During this period, the Register of Members and Share Transfer Books will be closed. The notice was signed by Peeyush Kumar Aggarwal, Managing Director.